Oncoxin nutritional supplement in the management of chemotherapy- and/or radiotherapy-associated oral mucositis

Abstract

Oral mucositis (OM) is a common and potentially dangerous complication of anticancer treatment. Since there are only few therapeutic options for OM, there is a need to identify novel approaches to its management and prevention. The aim of the present study was to evaluate the efficacy of Oncoxin (ONCX), a nutritional supplement that contains microelements, vitamins, amino acids and certain biologically active substances of natural origin, in cancer patients who receive chemotherapy, radiotherapy or a combination of the two. A total of 15 male and female patients (aged 45–75 years) with malignant neoplasms, who had been prescribed radiotherapy, chemotherapy or a combination of the two, with an Eastern Cooperative Oncology Group performance status score ≤3, and grade 2–3 OM based on the World Health Organization (WHO) Oral Toxicity Scale, were enrolled in a 20-day study; 10 patients were in the ONCX group and 5 served as controls. The patients were allowed to use any anticancer treatment and any type of OM care. In addition to their current treatment, patients in the ONCX group used 25 ml of the ONCX nutritional supplement twice daily for 20 days. The mean WHO Oral Toxicity Scale grade decreased by 41% in the ONCX group after ~7 days from the beginning of the study compared with minimal change in the control group. At the end of the study, the difference was even more prominent, with a 73 and 20% decrease from baseline in the ONCX and control groups, respectively (P<0.001). During the entire trial period, patients in the ONCX group were able to eat normally during 65% of the time, in contrast to only 29% in the control group (P=0.04). There were no statistically significant changes in absolute body mass, or in the number of days with normal appetite. This was a pilot study aiming to show the benefits of the ONCX nutritional supplement in OM, and the results demonstrated that ONCX rapidly improved the symptoms of OM and helped to maintain normal eating habits in patients undergoing cancer treatment.

Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review

“…Moreover, by the end of three weeks, the level of albumin was higher in the OOS cohort and liver toxicity was lower in that cohort. Benefits of OOS in patients treated with chemotherapy or radiotherapy were also observed by Shumsky et al [76], who studied the impact of OOS on oral mucositis in 15 patients, 10 treated with OOS and five control. Using the World Health Organization Oral Toxicity Scale, the authors reported a 41% decrease in oral mucositis in the OOS-treated group as compared to minimal change in the control group, which was allowed to use other types of care for oral mucositis.…”

Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy

“…Oncoxin is a solution containing amino acids, vitamins, micronutrients and biologically active substances. Previous studies showed that ONCX was able to increase life expectancy, improve QoL and appetite in patients with end-stage hepatocellular carcinoma (10) and effectively reduce the severity of oral mucositis symptoms in patients receiving CT, radiation therapy or their combination (11).…”

Ocoxin as a complement to first line treatments in cancer

“…Besides, Ocoxin abrogated hepatic-toxicity related ALT and AST enzyme increase in 92% of the patients under adjuvant CT regiment after 3 weeks of treatments, while only the AST and ALT levels of 50% of the patients from non-supplemented group remained unchanged. This reduced hepatic toxicity was further confirmed by Shumsky et al (2019) in patients receiving Ocoxin to mitigate CT and RT related oral mucositis [55]. They reported 4 and 7-fold reduced ALT and AST levels in patients under Ocoxin supplementation compared to those receiving CT and RT.…”

“…This damage is partly mediated by inflammatory mediators such as IL-1β, TNF-α and inducible nitric oxidase sinthase (iNOS) 53 , 54 . Interestingly, Ocoxin exerts a curative effect in patients suffering from this side effect, diminishing the ulcerative area and facilitating the healing of the affected tissue 55 , therefore eliminating the pain related to eating and drinking. This effect may be due to the anti-inflammatory properties of Ocoxin, which confers the ability to inhibit TNF-α upregulation, as reported in other pathologies 25 .…”